Relevant to Claim No.

A. CLASSIFICATION OF SUBJECT MATTER.

Int. Cl.⁷ C07F 15/00; A61K 31/555, 33/24; A61P 35/00.

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

bategory*

Minimum documentation searched (classification system followed by classification symbols See electronic database consulted below.

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic database consulted during the international search (name of database, and where practicable, search terms used) STN Substructure Search

STN (Medline, CA, WPIDS): Keywords-isoflav?, genistein, daidzein, flavan?, flavon?, platin?, cisplat?

Citation of document, with indication, where appropriate, of the relevant passages

C. DOCUMENTS CONSIDERED TO BE RELEVANT

					Claim No.	
	X		es (8 Feb	per 2002151803 oruary 2002), 70(12), pages 1447-1459, omplex (IdB 1016) potentiate in vitro and in		
X		STN File Medline, abstract accession number 2000404390 & S. Caltagirone et al., International Journal of Cancer (15 August 2000), 87(4), pages 595-600, 'Flavonoids apigenin and quercetin inhibit melanoma growth and metastatic potential'.				
* "A" "E" "L"	documer which is relevanc earlier a after the	pplication or patent but published on or international filing date	"T"	later document published after the international filing data and not in conflict with the application but cited to under or theory underlying the invention document of particular relevance; the claimed invention considered novel or cannot be considered to involve an invented to the document is taken alone document of particular relevance; the claimed invention of the document of particular relevance;	stand the principle cannot be nventive step cannot be	
claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified) "O" document referring to an oral disclosure, use, exhibition or other means		1	considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art document member of the same patent family			
	date but	nt published prior to the international filing later than the priority date claimed al completion of the international-type search	 1	Date of mailing of the international-type search repo	rt	
		ng address		Authorized Officer		

MARIE-ANNE FAM


Telephone No. (02) 6283 2254

Facsimile No. (02) 6285 3929

AUSTRALIAN PATENT OFFICE

E-mail address: pct@ipaustralia.gov.au

PO BOX 200, WODEN ACT 2606, AUSTRALIA



ategory*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to Claim No.
X	STN File Medline, abstract accession number 96273517 & G. Scambia et al., European Journal of Cancer (May 1996), 32A(5), pages 877-882, 'Antiproliferative effect of silybin on gynaecological malignancies: synergism with cisplatin and doxorubicin'.	Cidili 130.
X	STN File Medline, abstract accession number 91191699 & W. R. Waud et al., Cancer Chemotherapy and Pharmacology (1991), 27(6), pages 456-463, 'Antitumor drug cross-resistance in vivo in a cisplatin-resistant murine P388 leukemia'.	
X	STN File Medline, abstract accession number 91107211 & S. S. Neelam et al., Investigational New Drugs (August 1990), 8(3), pages 263-268, 'Combination of flavone acetic acid (FAA) with adriamycin, cisplatinum and difluoromethylornithine (DFMO) in vitro against human colon cancer cells'.	
x	STN File Medline, abstract accession number 92032982 & G. Scambia et al., Anti-Cancer Drugs (October 1990), 1(1), pages 45-48, 'Synergistic antiproliferative activity of quercetin and cisplatin on ovarian cancer cell growth'.	
x	STN File CA, abstract number 119:131038 & R. De Vincenzo et al, Acta Medica Romana (1992), 30(1-2), pages 126-132, 'Flavonoids and negative control of cell proliferation in ovarian tumors'.	
X	Acta Poloniae Pharmaceutica Drug Research, 1999, 56(2), pages 159-167, E. Zyner and J. Ochocki, 'Platinum (II) and palladium (II) N, O-chelates with substituted flavanone containing ligands'. (see the whole document, in particular page 162, scheme 1 and page 164, table 1)	
х	Pharmazie, 1999, 54(12), pages 945-946, E. Zyner et al., 'Pt(II) and Pd(II) complexes of 3-aminoflavone: in vitro and in vivo evaluation'. (see the whole document)	
X	Anticancer Research, 1999, volume 19, pages 221-228, W. Lei et al., 'Enhancement of chemosensitivity and programmed cell death by tyrosine kinase inhibitors correlates with EGFR expression in non-small cell lung cancer cells'. (see the whole document, in particular the abstract and page 224)	
х	Pediatric Neurosurgery, 2000, volume 33, pages 123-131, S. Khoshyomn et al., 'Synergistic action of genistein and cisplatin on growth inhibition and cytotoxicity of human medulloblastoma cells'. (see the whole document)	

C (Continu	C (Continuation). DOCUMENTS CONSIDERED TO BE RELEVANT					
Category*	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to Claim No.				
X	Natural Product Sciences, 2000, 6(4), pages 165-169, B-J. Kang et al., 'Scientific analysis of formulation theory of Chungpesagan-tang; in vitro cytotoxicity of cisplatin combined with Chungpesagan-tang'.					
	(see the whole document, in particular the abstract and page 168)	:				
1						
		į				
	÷ .					